2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 1930

Interleukin 1β Decreases Capacity for Repair Human Cartilage Lesions By Mesenchymal Stromal Cells on Collagen/Proteoglycan Scaffolds

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2574

Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation

Systemic Lupus Erythematosus – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2114

Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2166

Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2174

Investigating Exercise- and Crossfit-Induced Rhabdomyolysis: Data from a Community Healthcare System

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2211

Investigation of Self-Reported Painful Joint Count As an Outcome Measure in Hand Osteoarthritis

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 2228

Involvement of Receptor Tyrosine Kinase a Signaling in Rhumatoid Arthritis Using Trka/C Knock-in Mice: A Multimodal Approach

Pain – Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 2511

Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2181

Is a Decrease in MRI-Defined Inflammation Associated with a Decrease in Pain in Patients with Hand Osteoarthritis? a Two-Year Follow-up Study

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 2718

Is Smoking Important in Adult IgA Vasculitis?

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2735

Is There an Association between Adult IgA Vasculitis and Cancer?

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2304

Joint Injection Practices in Pediatric Rheumatology – Preliminary Data from an Ongoing Web Based Survey

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2130

Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2389

Joint Surgery in Rheumatoid Arthritis 1980-2013: A Population-Based Study to Identify Risk Factors and Time Trends in Incidence

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2414

Knowledge and Adherence to Current Immunization Recommendations in Patients with Rheumatoid Arthritis in Mexico

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].